Authors


Robert J. Soiffer, MD

Latest:

Soiffer Discusses Relapse After Transplant

Robert J. Soiffer, MD, discusses the role of transplantation and relapse after transplant for patients with cancer.


Ashley Chan

Latest:

Abiraterone, Prednisone, Apalutamide Improves Prostate Cancer Outcomes, Leaves HRQoL Unaffected

Oncological outcomes improved with the addition of abiraterone acetate (Zytiga) plus prednisone (AAP) and apalutamide (Erleada) after radical prostatectomy and did not significantly affect health-related quality of life.


Susan C. Modesitt, MD

Latest:

Tisotumab Vedotin Improves Treatment Options in Cervical Cancer

Susan C. Modesitt, MD, discusses the introduction of antibody drug conjugate tisotumab vedotin to treatment for patients with metastatic cervical cancer.


Jim Kling

Latest:

ctDNA Pushes Its Prognostic Role in Large Cell Lymphomas

For large cell lymphomas, physicians typically use CT and positron emission tomography-computed tomography scans to look for signs of minimum residual disease when treatment is completed.



Rohit Gosain, MD

Latest:

The Role of Circulating Tumor DNA in Bladder Cancer

Following a discussion centered on the EV-302 study, Thomas Powles, MBBS, MRCP, MD, and the Oncology Brothers discuss the role of circulating tumor DNA in urothelial cancer.


Yazan Madanat, MD

Latest:

Key Updates in Lower-Risk MDS

In the fifth article of this series, Yazan Madanat, MD, reviews recent updates presented at the 2023 ASH Annual Meeting and discusses the evolving treatment landscape.


Colin Vale, MD

Latest:

JAK Inhibitors Emerge as a Cornerstone Therapy for Myelofibrosis

With multiple JAK inhibitors now available to choose from, patient- and disease-specific factors are vital in determining the most appropriate therapy for patients with myelofibrosis.


Expert in oncology
Allison Betof Warner, MD, PhD

Latest:

Role of Tumor-Infiltrating Lymphocytes in Solid Tumors: Advancements in Therapeutic Strategy

In the first interview of this series, Allison Betof Warner, MD, PhD, reviews the mechanistic rationale of tumor-infiltrating lymphocytes and considers their potential use in the management of solid tumors.


Jordyn Sava

Latest:

Revolutionizing Cancer Care With Genomic Testing

In an interview with Targeted Oncology, David L. Bartlett, MD, discussed the utilization and growing importance of genomic testing in cancer care.


Peter Zang, MD

Latest:

Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.


John Nakayama, MD

Latest:

About NRG GY018: Pembrolizumab Plus Chemotherapy in Endometrial Cancer

John Nakayama, MD, discusses the significance of the NRG GY018 study in endometrial cancer.


Yazan Samhouri, MD

Latest:

Updates in the Management of Diffuse Large B-Cell Lymphoma

Yazan Samhouri, MD, discusses the latest advancements in the diffuse large B-cell lymphoma treatment landscape.


Jared Kaltwasser

Latest:

In Advanced Prostate Cancer, a String of Modest Gains Are Changing Patient Care

Robert Dreicer, MD, MS, MACP, FASCO, acknowledges that there have been substantial developments in therapies and strategies for treating prostate cancer, leading to heightened expectations of breakthroughs in the field.


Daniel Cancilla, MD

Latest:

Can New Protocols Reduce Costs of Multiple Myeloma Treatment?

Daniel Cancilla, MD, discusses a study performed at the Cleveland Clinic where a new protocol for plerixafor usage for stem cell transplantation was implemented with the goal of cost savings.


Alice Bertaina, MD, PhD

Latest:

Promising New Therapy for Hematologic Malignancies in Young Patients

Alice Bertaina, MD, discusses combining of T-allo10, a donor-derived cell product, with haploidentical stem cell transplants for the treatment of pediatric and young adult patients with hematologic malignancies.


Krina K. Patel, MD, MSc

Latest:

Unmet Needs in R/R MM and Clinical Practice Pearls

Closing their discussion, the panel highlights unmet needs in the management of relapsed/refractory multiple myeloma and shares clinical pearls for community physicians.


Chandler H. Park, MD

Latest:

Recent Trial Updates in Advanced Renal Cell Carcinoma (RCC)

In the second article of this series, Chandler H. Park, MD, a genitourinary oncologist at Norton Cancer Institute, reviews recently updated data on advanced renal cell carcinoma treatments.


Catherine C. Coombs, MD

Latest:

Unmet Needs and Clinical Pearls for Treating Relapsed/Refractory CLL

Catherine C. Coombs, MD, discusses unmet needs and offers advice for community oncologists treating patients with relapsed/refractory chronic lymphocytic leukemia.



Valentina Ardila, MD

Latest:

Obesity May Increase Chronic GVHD After Stem Cell Transplant

Valentina Ardila, MD, discusses findings from a study investigating the role of obesity in patients undergoing stem cell transplants.


Rogerio C. Lilenbaum, MD

Latest:

Molecular Testing Used for Patients With Non-Small Cell Lung Cancer

Rogerio C. Lilenbaum, MD, discusses molecular panels and other testing for patients with nonsquamous non-small cell lung cancer.


Paul Boutros, PhD, MBA

Latest:

Exploring the Reasons Why Certain Prostate Cancers Are More Aggressive

Paul Boutros, PhD, MBA, discusses the reasons why some patients with prostate cancer have more aggressive disease than others.


S. Michelle Shiller, DO, AP/CP, MGP

Latest:

Looking Towards the Future of Molecular Testing and Additional Treatment Options for Patients with mNSCLC

The panel closes by summarizing recent advances in the field and shares hopes for future improvements in molecular testing and treatment options for patients with mNSCLC.


Radhika Takiar, MD

Latest:

The Role of Targeted Therapies in Frontline Treatment of Mantle Cell Lymphoma

There have been marked improvements in expected remission and overall survival rates in mantle cell lymphoma even though a cure for this disease remains elusive.


Naomi Haas, MD

Latest:

Factors Influencing Frontline Therapy Options for Favorable-Risk RCC

Naomi B. Haas, MD, discusses the choice of frontline treatment for favorable-risk patients with advanced clear cell renal cell carcinoma.


Janna Afanasjeva, PharmD, BCPS

Latest:

Improved Sensitivity, Monitoring Needed for MRD in Adult and Pediatric ALL

Despite advances with MRD monitoring, further research and practice advances are needed to continue the trend for improving outcomes in patients with acute lymphoblastic leukemia.


Jimmy Caudell, MD, PhD

Latest:

Varying Incidence of HPV-Positive and Negative Oropharyngeal Cancers

Jimmy Caudell, MD, PhD, discusses the overall incidence of human papillomavirus-positive and negative oropharyngeal cancers in the United States.


Jalal S. Baig, MD

Latest:

Multiple Factors at Play in the Rise of Early-Onset Colorectal Cancer

Oncologists are seeing early onset colorectal cancer more frequently, according to Jalal S. Baig, MD, medical oncologist at City of Hope Chicago.


Martee Hensley, MD

Latest:

The Future of Research in PEComas

The panel shares future areas of research in malignant PEComa that interest them, and how they see the treatment landscape evolving.